Classifications: antilipemic; hmg-coa reductase inhibitor (statin); Therapeutic: antilipemic; statin
Pregnancy Category: X
10 mg, 20 mg, 40 mg, 80 mg tablets
Competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes cholesterol biosynthesis.
HMG-Coa reductase inhibitors (statins) increase serum HDL cholesterol, decrease serum LDL cholesterol, VLDL cholesterol,
and plasma triglyceride levels.
It is effective in reducing total and LDL cholesterol in various forms of hypercholesterolemia.
Hypercholesterolemia (alone or in combination with bile acid sequestrants) and familial hypercholesterolemia.
Hypersensitivity to pravastatin; active liver disease or unexplained elevated liver function test; hepatic encephalopathy,
hepatitis, jaundice, rhabdomyolysis; pregnancy (category X), lactation. Safety and efficacy in children less than 8 y are
Alcoholics, history of liver disease; renal impairment; renal disease; seizure disorders.
Route & Dosage
Adult: PO 1080 mg q.d.
Child (813 y): PO 20 mg q.d.
- Give without regard to meals.
- Give in the evening.
Adverse Effects (≥1%)GI:
, abdominal pain, vomiting, constipation
, flatulence, heartburn, transient elevations in serum
levels. Other: Fatigue
, rhinitis, cough, transient elevations in CPK.
May increase PT when administered with warfarin.
Poorly from GI tract; 17% reaches systemic circulation. Onset:
2 wk. Peak:
4 wk. Distribution:
4355% protein bound; does not cross bloodbrain barrier; crosses placenta; distributed into breast milk. Metabolism:
Extensive first-pass metabolism
in liver; has no active metabolites. Elimination:
20% of dose excreted in urine, 71% in feces. Half-Life:
Assessment & Drug Effects
- Lab tests: Perform liver function tests at start of therapy and then at 12 wk. If normal at 12 wk, may change to semiannual
monitoring. Monitor cholesterol levels throughout therapy.
- Monitor coagulation studies with patients receiving concurrent warfarin therapy. PT may be prolonged.
- Monitor CPK levels if patient experiences unexplained muscle pain.
Patient & Family Education
- Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever, to physician promptly.
- Report signs of bleeding to physician promptly when taking concomitant warfarin therapy.